Improving the Efficacy of EGFR Inhibitors by Topical Treatment of Cutaneous Squamous Cell Carcinoma with miR-634 Ointment

For cutaneous squamous cell carcinoma (cSCC), topical treatment is an essential option for patients who are not candidates for, or who refuse, surgery. Epidermal growth factor receptor (EGFR) plays a key role in the development of cSCC, but EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Jun, Fujiwara, Kyoko, Hamamoto, Hidetoshi, Kobayashi, Katsunori, Inazawa, Johji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695908/
https://www.ncbi.nlm.nih.gov/pubmed/33294587
http://dx.doi.org/10.1016/j.omto.2020.10.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695908/
https://www.ncbi.nlm.nih.gov/pubmed/33294587
http://dx.doi.org/10.1016/j.omto.2020.10.009

Ejemplares similares